Abstract
Proper selection of anesthetic technique is important in otologic surgical procedures. In the middle ear microsurgery an anesthetic agent must provide bloodless, good surgical field visibility for safe tympanic membrane reconstruction, safe ossicular reconstruction with respect to the basic anatomic structure of the middle ear. Additionally, no alteration of intratympanic pressure is acceptable during the anesthetic act and after its discontinuation. Consequently, postoperative nausea and vomiting should be minimal after tympanoplasty operations for the stability of tympanic graft and ossicles. Therefore, the anesthesiologist must use a technique that provides a sufficiently deep level of anesthesia with minimal intraoperative movement, rapid emergence, good hemodynamic control and tympanometric stability. Currently, many inhaler and intravenous (IV) anesthesia could be preferred for otologic surgical procedures and they offer ideal intraoperative conditions. Dexmedetomidine is a novel analgesic agent that helps this inhaler or IV anesthesia at preoperative state, postoperative period and during surgery especially for hemodynamic stability. In this article, pharmacocinetic properties of dexmedetomidine were described, its advantages for patients undergoing surgery,related patents and its role in otologic surgery were discussed.
Keywords: Dexmedetomidine, middle-ear surgery
Recent Patents on CNS Drug Discovery (Discontinued)
Title: Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Volume: 2 Issue: 2
Author(s): Yezdan Firat and Erol Selimoglu
Affiliation:
Keywords: Dexmedetomidine, middle-ear surgery
Abstract: Proper selection of anesthetic technique is important in otologic surgical procedures. In the middle ear microsurgery an anesthetic agent must provide bloodless, good surgical field visibility for safe tympanic membrane reconstruction, safe ossicular reconstruction with respect to the basic anatomic structure of the middle ear. Additionally, no alteration of intratympanic pressure is acceptable during the anesthetic act and after its discontinuation. Consequently, postoperative nausea and vomiting should be minimal after tympanoplasty operations for the stability of tympanic graft and ossicles. Therefore, the anesthesiologist must use a technique that provides a sufficiently deep level of anesthesia with minimal intraoperative movement, rapid emergence, good hemodynamic control and tympanometric stability. Currently, many inhaler and intravenous (IV) anesthesia could be preferred for otologic surgical procedures and they offer ideal intraoperative conditions. Dexmedetomidine is a novel analgesic agent that helps this inhaler or IV anesthesia at preoperative state, postoperative period and during surgery especially for hemodynamic stability. In this article, pharmacocinetic properties of dexmedetomidine were described, its advantages for patients undergoing surgery,related patents and its role in otologic surgery were discussed.
Export Options
About this article
Cite this article as:
Yezdan Firat and Erol Selimoglu , Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery, Recent Patents on CNS Drug Discovery (Discontinued) 2007; 2 (2) . https://dx.doi.org/10.2174/157488907780832760
DOI https://dx.doi.org/10.2174/157488907780832760 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology Natural Compounds with Cell Growth Inhibitory Activity in Human Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Altered Calcium Handling in Reperfusion Injury
Medicinal Chemistry The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Consumer Understanding and Use of Health Claims: The Case of Functional Foods
Recent Patents on Food, Nutrition & Agriculture Is Fast Food Addictive?
Current Drug Abuse Reviews Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry B-Type Natriuretic Peptide for Diagnosis and Therapy
Recent Patents on Cardiovascular Drug Discovery Pre-procedural Elevated White Blood Cell Count and Neutrophil-Lymphocyte (N/L) Ratio are Predictors of Ventricular Arrhythmias During Percutaneous Coronary Intervention
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Agents Against COVID-19 with Clinical Evidence
Current Pharmaceutical Design Recent Advances in Fe-MOF Compositions for Biomedical Applications
Current Medicinal Chemistry Potential Linkage Between Cerebrovascular Diseases and Metabolic Syndrome
Current Drug Metabolism Alzheimers Disease and Intelligence
Current Alzheimer Research Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews